Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Clarus Therapeutics Holdings, Inc. (CRXTQ) had Revenue of $13.96M for the most recently reported fiscal year, ending 2021-12-31.

Quarterly Annual

Figures for fiscal year ending 2021-12-31

Income Statement Financials
Revenue	$13.96M
Net Income	$-40.62M
Cost of Goods Sold	$2.72M
Gross Profit	$11.24M
Operating Expenses	$53.69M
Operating Income	$-39.73M
Non-Operating Income/Expense	$-0.89M
Pre-Tax Income	$-40.62M
Normalized Pre-Tax Income	$-40.62M
Income after Taxes	$-40.62M
Income from Continuous Operations	$-40.62M
Consolidated Net Income/Loss	$-40.62M
Normalized Income after Taxes	$-40.62M
EBIT	$-39.73M
EBITDA	$-39.71M
Weighted-Average Shares Outstanding (Basic)	7.03M
Weighted-Average Shares Outstanding (Diluted)	7.03M
Earnings per Share (EPS) (Basic)	$-5.72
Earnings per Share (EPS) (Diluted)	$-5.72
Balance Sheet Financials
Current Assets	$51.64M
Property, Plant, and Equipment	$0.07M
Long-Term Assets	$0.07M
Total Assets	$51.71M
Current Liabilities	$66.06M
Long-Term Debt	--
Long-Term Liabilities	$1.57M
Total Liabilities	$67.63M
Common Equity	$-15.92M
Tangible Shareholders Equity	$-15.92M
Shareholders Equity	$-15.92M
Common Shares Outstanding	24.03M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-43.79M
Cash Flow from Investing Activities	$-0.03M
Cash Flow from Financial Activities	$62.99M
Beginning Cash	$7.23M
End Cash	$26.41M
Increase/Decrease in Cash	$19.18M
Stock-Based Compensation	$0.67M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	0.78
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	-2.66
Gross Margin	80.51%
Operating Margin	-284.67%
EBIT Margin	-284.67%
EBITDA Margin	-284.50%
Pre-Tax Profit Margin	-291.02%
Profit Margin	-291.02%
Free Cash Flow	$-43.81M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.27
Inventory Turnover	0.19
Receiveable Turnover	2.20
Days Sales in Receivables	165.83
Return on Equity	255.15%
Return on Tangible Equity	255.15%
Return on Assets	-78.55%
Return on Investments	255.15%
Book Value Per Share	$-0.66
Free Cash Flow per Share	$-6.23
Operating Cash Flow per Share	$-6.23

Data from Zacks Investment Research, Inc.